ArticleScientific reports2026
Organophosphate pesticide DEDT promotes diabetic retinopathy progression via AMPK/Nrf2/HO-1 pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The impact of environmental toxins, particularly organophosphate pesticides (OPs), on the progression of diabetic retinopathy (DR) remains insufficiently understood. Recent studies have highlighted the potential role of environmental pollutants in exacerbating diabetic complications, but the underlying mechanisms are still unclear. This study aims to explore the effect of diethyldithiophosphate (DEDT), an OP, on DR progression through modulation of the AMPK/Nrf2/HO-1 signaling pathway. Human retinal microvascular endothelial cells (HRMECs) and retinal pigment epithelial cells (ARPE-19) were cultured under high-glucose conditions to simulate diabetic stress. Cells were exposed to various concentrations of DEDT, and their viability, oxidative stress, tight junction integrity, and inflammation were assessed. Western blot, quantitative PCR, and enzyme-linked immunosorbent assay (ELISA) techniques were employed to evaluate the expression of key proteins in the AMPK/Nrf2/HO-1 pathway and inflammatory cytokines. In vivo, diabetic rat models were treated with DEDT to assess retinal damage and oxidative stress. The effects of AMPK activation were also evaluated using AICAR, an AMPK activator, to further explore the mechanistic role of AMPK/Nrf2/HO-1 signaling. Our results demonstrated that DEDT exposure significantly reduces retinal cell viability and disrupts tight junction proteins (ZO-1, Occludin, Claudin-5) under high-glucose conditions. Mechanistically, DEDT inhibited the AMPK/Nrf2/HO-1 pathway, leading to increased oxidative stress, enhanced inflammation, and elevated levels of apoptotic markers (Bax and Bcl-2). In vivo, DEDT exposure exacerbated retinal damage and oxidative stress in diabetic rats. Activation of AMPK by AICAR reversed these effects, restoring Nrf2 and HO-1 expression, improving cell viability, and protecting the blood-retinal barrier. These findings indicated that DEDT promotes DR progression by disrupting the AMPK/Nrf2/HO-1 signaling pathway. This study provided experimental evidence that DEDT accelerates diabetic retinopathy progression via inhibition of the AMPK/Nrf2/HO-1 pathway, contributing to increased oxidative stress and retinal barrier dysfunction. Our results emphasized the potential health risks associated with pesticide exposure, particularly in diabetic populations, and highlight the importance of regulating environmental toxins to prevent exacerbation of diabetic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.